Clinical trial
Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)
NCT04439110
Study timeline
Study start (actual)2015-08-12Date precision: day
Registry last updated2026-05-08
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Advanced Lymphomaunresolved
Advanced Malignant Solid Neoplasmunresolved
Hematopoietic and Lymphoid Cell Neoplasmunresolved
Refractory Lymphomaunresolved
Refractory Malignant Solid Neoplasmunresolved
Refractory Multiple Myelomaunresolved
Interventions
Trastuzumab EmtansineBIOLOGICAL
Sponsors & collaborators
National Cancer Institute (NCI)lead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04439110 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.